Intraglandular botulinum neurotoxin (BoNT) injection vs placebo injection
Adverse events (participants with >=1 adverse event) · Adults with Parkinson's disease and sialorrhea (drooling)
Type A botulinum toxin showed a borderline, non-significant increase in adverse events versus placebo (RD 0.10, 95% CI 0.00 to 0.21; ungraded subgroup).
3 findings from 1 review
- The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomesApproximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) · BoNT type ARD 0.10 [0.00, 0.21]5 studies · 117 participantsGRADE not reported
- The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomesApproximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia)RD 0.15 [0.05, 0.24]10 studies · 249 participantsLow
- The effectiveness and safety of botulinum toxin injections for the treatment of sialorrhea with Parkinson's disease: a… 2023 All outcomesApproximately 1 month post-injection (one study ~1 week) · Movement-disorder / neurology outpatient care (trials from Italy, USA, and Estonia) · BoNT type BRD 0.18 [0.04, 0.33]5 studies · 132 participantsGRADE not reported